...
首页> 外文期刊>Current opinion in allergy and clinical immunology >Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
【24h】

Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.

机译:选择性磷酸二酯酶抑制剂,用于治疗哮喘和慢性阻塞性肺疾病。

获取原文
获取原文并翻译 | 示例
           

摘要

Phosphodiesterase type 4 plays an important role in modulating the activity of cells that are involved in the inflammatory processes occurring in chronic obstructive pulmonary disease and asthma. During the past decade, interest has focused on the development of selective inhibitors of phosphodiesterase-4, in an attempt to generate new treatment modalities that control airway inflammation not only in patients with asthma but also in those with chronic obstructive pulmonary disease. The aim of the present review is to discuss the results of recent clinical intervention studies with phosphodiesterase-4 inhibitors in patients with asthma or chronic obstructive pulmonary disease.
机译:4型磷酸二酯酶在调节参与慢性阻塞性肺疾病和哮喘发炎过程的细胞活性中起重要作用。在过去的十年中,人们的兴趣集中在磷酸二酯酶-4选择性抑制剂的开发上,试图产生不仅控制哮喘患者而且控制慢性阻塞性肺疾病患者的气道炎症的新治疗方式。本综述的目的是讨论最近在哮喘或慢性阻塞性肺疾病患者中使用磷酸二酯酶-4抑制剂进行临床干预研究的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号